Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0UVYLY)
| ADC Name |
SYS6005
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
SYS6005; SYS6005Y; SYSY2107; RB-164
Click to Show/Hide
|
|||||
| Organization |
CSPC Pharmaceutical Group (Originator);Radiance
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Anti-ROR1 Fc-silenced mAb
|
Antibody Info | ||||
| Antigen Name |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
|||||
| Unspecific non-hodgkin lymphoma |
1 Trials
|